Passive Oral Immunization by Egg Yolk Immunoglobulin (IgY) to Vibrio cholerae Effectively Prevents Cholera by Hirai, Kazuyuki et al.
Acta Medica Okayama
Volume 64, Issue 3 2010 Article 2
JUNE 2010
Passive Oral Immunization by Egg Yolk
Immunoglobulin (IgY) to Vibrio cholerae
Effectively Prevents Cholera
Kazuyuki Hirai, Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences
Hideyuki Arimitsu, Department of Microbiology, Fujita Health University, School of Medicine
Koji Umeda, Immunology Research Institute, GHEN Corporation
Kenji Yokota, Graduate School of Health Sciences, Okayama University
Lianhua Shen, Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences
Kiyoshi Ayada, Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences
Yoshikatsu Kodama, Immunology Research Institute, GHEN Corporation
Takao Tsuji, Department of Microbiology, Fujita Health University, School of Medicine
Yoshikazu Hirai, Division of Infection and Immunuity, Jichi Medical School
Keiji Oguma, Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences
Copyright c©1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.
Passive Oral Immunization by Egg Yolk
Immunoglobulin (IgY) to Vibrio cholerae
Effectively Prevents Cholera
Kazuyuki Hirai, Hideyuki Arimitsu, Koji Umeda, Kenji Yokota, Lianhua Shen,
Kiyoshi Ayada, Yoshikatsu Kodama, Takao Tsuji, Yoshikazu Hirai, and Keiji
Oguma
Abstract
In an attempt to prepare egg yolk immunoglobulin (IgY) to treat and prevent cholera, hens
were immunized by a mixture of heat- or formalin-killed Vibrio cholerae O1 and O139 organisms,
or by the recombinant cholera toxin B subunit (CTB). The IgYs were partially purified from egg
yolk and orally administered to suckling mice before or after challenge with live O1 or O139
cells. The anti-O1 and O139 IgYs and the mixture of either IgY with anti-CTB IgY significantly
protected the occurrence of cholera caused by both O1 and O139 infection. Since large amounts of
IgY can be prepared very easily and at low cost, this seems to be a useful procedure for preventing
and treating cholera.
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In an attempt to prepare egg yolk immunoglobulin (IgY) to treat and prevent cholera,  hens were 
immunized by a mixture of heat- or formalin-killed Vibrio cholerae O1 and O139 organisms,  or by the 
recombinant cholera toxin B subunit (CTB).  The IgYs were partially puriﬁed from egg yolk and 
orally administered to suckling mice before or after challenge with live O1 or O139 cells.  The anti-O1 
and O139 IgYs and the mixture of either IgY with anti-CTB IgY signiﬁcantly protected the occurrence 
of cholera caused by both O1 and O139 infection.  Since large amounts of IgY can be prepared very 
easily and at low cost,  this seems to be a useful procedure for preventing and treating cholera.
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holera is an intestinal infection caused by Vibrio 
cholerae that leads to a severe diarrheal disease.  
In 2007,  a total of 177,963 cholera cases and 4,301 
deaths were oﬃcially reported to the World Health 
Organization (WHO) [1].  Every year,  more than 
100,000 people are infected,  of whom more than 90ｵ 
are Asian or African [2].  The strains of V. cholerae 
that cause epidemics belong to serogroups O1 and 
O139.  Many cases of V. cholera infection in travelers 
are also reported every year [1].  The principal symp-
tom is the painless purging of voluminous stools that 
resemble rice water and that are caused by cholera 
toxin (CT).  Since the patient becomes dehydrated,  
oral rehydration solution (ORS) is used as a general 
treatment [3].  Patients can recover by this treatment 
in many cases,  but even so they suﬀer from serious 
symptoms for long periods,  and sometimes the treat-
ment is not successful.  To prevent cholera,  2 kind of 
vaccines have been used: injectable vaccine and oral 
cholera vaccine (OCV).  The injectable vaccine is made 
from phenol-inactivated V. cholerae O1 and is still 
available.  However,  this vaccineʼs eﬃcacy ratio and 
its term reportedly are low and short,  respectively,  
and it has some side eﬀects.  In OCV,  3 types of 
preparations have been developed.  One is WC/rBS,  
which consists of inactivated V. cholerae O1 and 
recombinant cholera toxin B subunit (CTB).  WC/rBS 
provides 90ｵ protection in the ﬁrst 6 months and 
60ｵ protection for at least 3 years.  However,  pro-
tection in children aged under 5 years declines more 
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rapidly after 6 months,  protection is not conferred 
against O139 infection,  and the price is rather high 
(one dose is US$50).  In Vietnam,  the inactivated V. 
cholerae O1 and O139 without CTB were developed as 
the second type of OCV.  The cost was very low 
(under US$1 per dose),  but the protection rate was 
reported to be 66ｵ at 8 months across all ages.  The 
third OCV is the live O1 cells in which the gene of 
cholera toxin subunit A is deleted.  This OCV showed 
high protection eﬃcacy against V. cholerae O1 in chal-
lenge studies in the United States.  On the other hand,  
a large ﬁeld trial performed in Indonesia did not show 
convincing protection in a population exposed to chol-
era for a long time after immunization [4].  The vac-
cines may be eﬀective if they are used precisely,  but 
they may take a long time and require a lot of ﬁnancial 
support.  WHO has considered that V. cholerae O139 
still has the potential to cause the next cholera pan-
demic,  and it is possible that big outbreaks will occur 
after serious disasters such as earthquakes and ﬂoods.
　 In this manuscript,  we have investigated whether 
or not the egg yolk immunoglobulin (IgY) against 
cholera organisms (a mixture of O1 and O139 inacti-
vated with heat or formalin) and the B subunit of 
cholera toxin can be used to prevent and treat cholera 
because 1) large quantities of IgY can be isolated 
from the yolk by simple,  low-cost methods and without 
distress to the birds [5],  and 2) their value has 
already been reported in infection with rotavirus,  
parvovirus,  E. coli,  S. typhimirium,  S. mutans,  H. 
pylori,  and P. gingivalis [6-9].  These antibodies were 
designated as anti-V.C IgY and anti-CTB IgY,  and 
each antibody or a mixture of them was orally inocu-
lated into suckling mice before or after the challenge 
with V. cholerae O1 or O139.
Materials and Methods
　 Bacterial strains. V. cholerae O1 El Tor 
(Inaba) and (Ogawa),  isolated from a river in Ban-
gladesh,  were kindly provided by Dr. S. Miyoshi,  
Department of Environmental Health and Micro-
biology,  Okayama University Graduate School of 
Medicine,  Dentistry and Pharmaceutical Sciences.  
Also,  V. cholerae O139,  isolated from patients in 
India,  was provided by Dr. K. Okamoto,  Department 
of Gene Function,  Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences.
　 Anti-V. cholerae IgY and anti-CTB IgY 
preparation. IgY against V. cholerae organisms 
(anti-V.C IgY) and CTB (anti-CTB IgY) were pre-
pared.  V. cholerae O1 El Tor (Inaba) and O139 were 
grown in 400ml of brain heart infusion (BHI) broth 
for 15h at 37℃ with continuous shaking at 100rpm.  
Bacteria were harvested by centrifugation for 15min 
at 11,380×g at 4℃.  These were washed twice with 
sterile phosphate-buﬀered saline (PBS; pH7.2) and 
suspended.  O1 and O139 cells (each 1.5×1010 CFU/
ml) were inactivated by treatment with 0.5ｵ forma-
lin-PBS overnight,  or by heat (80℃ for 20min).  
These formalin- or heat-inactivated V. cholerae O1 and 
O139 organisms (a total of 4) were mixed together in 
equal proportions and used as an immunogen to hens.
　 Also,  recombinant CTB prepared as reported pre-
viously was used as an immunogen [10].  These anti-
gens were mixed with an equal volume of Freundʼs 
complete adjuvant (FIA) and immunized into 5-month-
old White Leghorn hens (strain Hyline W36; GHEN 
Corporation,  Gifu,  Japan) according to the method 
described by Yokoyama et al. [11].  To prepare anti-
V.C IgY,  the mixture (0.5ml) was injected into both 
breast muscles,  and a booster was given in the same 
manner at 6 weeks after the initial immunization.  
Also,  anti-CTB IgY was produced by immunization 
with 0.1mg/ml CTB,  followed by a booster (0.5mg 
CTB/ml) at 6 weeks after the initial immunization.  
The eggs were harvested daily throughout the third 
and fourth weeks after the booster and stocked at 
4℃.  The yokes were separated carefully from the 
albumin and yolk membrane.  The yokes was pooled,  
homogenized,  ﬁltrated through Teﬂon ﬁlter cloth,  and 
then partially puriﬁed by ammonium sulfate.  The 
precipitated IgY was suspended in PBS,  dialyzed,  
and freeze-dried in a freeze-drying machine (Labconco 
LL-12,  Labconco Corp.,  Kansas City,  MO,  USA).  
Control IgY powder was prepared from eggs from non-
immunized hens in the same manner.
　 Reactivity of IgY against V. cholerae and 
CTB. The reactivity of the IgY preparations 
(0.1mg/ml) to the cells and CTB was analyzed by 
enzyme-linked immunosorbent assay (ELISA).  A 
96-well microtiter plate was coated with CTB 
(1µg/100µl/well) or inactivated O1 or O139 cells 
(OD600＝0.1 7.5×107 CFU/ml,  100µl/well) in 
0.1M carbonate-bicarbonate buﬀer (pH9.6) at 4℃ 
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overnight.  After blocking with 200µl of PBS contain-
ing 10ｵ skim milk,  the wells were incubated with 
100µl of 1µg/well and 100µg/well of IgY for 2h at 
room temperature.  The wells were then incubated 
with horseradish peroxidase (HRP)-labeled anti-
chicken IgY (Medical & Biological Laboratories,  
Nagoya,  Japan).  Between each step,  the cells were 
washed extensively with PBS containing 0.05ｵ 
Tween 20.  Color was developed with o-phenylenedi-
amine and H2O2.  The reaction was terminated by 6 N 
H2SO4 and optical density (OD) was measured at 
490nm.  All treatments were replicated three times 
and reported as averages.
　 CHO assay. Chinese Hamster Ovary (CHO) 
cells were maintained in DEME with 10ｵ fetal calf 
serum (FCS) [12].  The cells were trypsinized and 
re-suspended in DEME with 1ｵ FCS.  Cells were 
pretreated with 2-60µg/ml of anti-CTB IgY,  10ng/
ml CT (List Biological Laboratories,  Campbell,  CA,  
USA) was added to the cells.  After 12h,  morpho-
logical change was observed under a microscope.
　 Eﬀect of IgY on cholera in infant mice.
Since V. cholerae causes diarrhea and death in suckling 
mice younger than about 10 days [13],  4-day-old 
suckling mice were infected [14,  15].  O1 and O139 
cells were separately cultured for 12h at 30℃ in 
400ml of BHI broth with shaking,  washed twice with 
PBS,  and re-suspended into PBS at 7.5×108 CFU/
ml.  Four h after the mice were separated from their 
mother,  each cell suspension (50µl) thus prepared was 
intragastrically inoculated into the mice using a 
syringe with a ﬂexible needle by oral administration 
[14].  Three h after this inoculation,  the mice were 
then administered 50µl of each (1mg/ml) of 3 IgYs 
(anti-V.C,  anti-CTB,  or the mixture of them),  and 
returned to their mothers.  Thereafter,  the surviving 
mice were repeatedly administered with the same IgY 
for up to 72h with diﬀerent intervals (every 2,  4,  6,  
or 12h) in order to study the therapeutic eﬀects.  To 
assess the prevention eﬀect,  each IgY preparation 
described above was mixed with O1 or O139 cells (the 
ﬁnal IgY and cell concentrations were 1mg and 7.5×
108 CFU/ml,  respectively),  and 50µl of the mixture 
was orally inoculated.
Results
　 Reactivity of anti-V.C IgY and anti-CTB IgY 
to bacterial cell or cholera toxin. The reactiv-
ity of anti-V.C-IgY and anti CTB-IgY to the diﬀerent 
antigens was measured by ELISA (Table 1).  Anti-
CTB IgY well reacted with not only recombinant CTB 
but also whole cholera toxin.  The anti-V.C IgY that 
was obtained by immunization with the mixture of O1 
El Tor (Inaba) and O139 reacted with all 6 kinds of 
bacterial antigens including heat- or formalin-killed V. 
cholerae O1 Ogawa.  As expected,  anti-CTB IgY and 
anti-V.C IgY did not react with bacteria and CTB (or 
cholera toxin),  respectively.
　 Prevention of anti-CTB IgY against morpho-
logical change in CHO cells. CHO cells changed 
morphologically from a round or ﬂat shape to an elon-
gated spindle shape after the addition of 10ng/ml CT 
(Fig.  1A-1 and 2) [12].  The eﬀect of anti CTB-IgY 
on this change was observed.  CHO cells were treated 
with 2-60µg/ml of anti CTB-IgY and then challenged 
with CT (10ng/ml).  The IgY prevented the morphol-
ogy change dose-dependently (0-20µg/ml) (Fig.  
1A-(3) and 1B).
　 Therapeutic eﬀect of oral administration of 
IgY. Suckling mice were infected with V. cholerae 
O1 El Tor (Inaba) or O139,  and then,  3h later,  were 
treated with 50µl of anti-V.C IgY,  anti-CTB IgY,  or 
a mixture of them (each 1mg/ml) was performed at a 
2h interval,  as described in Materials and Methods.  
Anti-V.C IgY prevented the death of almost all the 
mice infected with V. cholerae O139 (Fig.  2B),  but did 
not prevent the death of mice infected with V. cholerae 
O1 El Tor (Inaba).  In the latter case,  death was 
highly prevented by the mixture of anti-V.C IgY and 
anti-CTB IgY (Fig.  2A).  We then,  investigated the 
eﬀect of IgY administration at diﬀerent intervals.  The 
mixture of anti-V.C IgY and anti-CTB IgY was admin-
istered at 2,  4,  6,  8,  or 12h intervals after 3h of V. 
cholerae O1 El Tor (Inaba) infection (Fig.  2C).  The 
mice survived at high rates after the 4,  6,  and 8h 
intervals as well as after the 2h interval; the rates 
were 80ｵ after 4h and 70ｵ after 6 or 8h (Fig.  
2C).
　 Protective eﬀect of passive immunization 
with IgY. Diﬀerent amounts of anti-V.C IgY 
(2mg,  1mg,  0.5mg/ml) were mixed with V. cholerae 
O1 El Tor (Inaba) and then orally inoculated into 
suckling mice.  The anti-V.C IgY showed a strong 
protective eﬀect even though 0.5mg/ml was employed 
(Fig.  3A-1),  and a similar eﬀect was observed when 
165Eﬃcacy of the Anti-cholera IgYJune 2010
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the V. cholerae O139 was mixed with 1mg/ml of anti-
V.C IgY (Fig.  3A-2).  We then investigated the pro-
tective eﬀect of IgY administered before cell infection.  
Suckling mice were administered a mixture of anti-V.
C and CTB IgY (each 1mg/ml).  After 1h,  V. cholerae 
O1 El Tor (Inaba) was challenged.  The survival time 
became longer in the IgY-treated group than in the 
control,  and 30ｵ of those in the former group sur-
vived (Fig.  3B).
Discussion
　 We have shown in a mouse model that the mixture 
of anti-V.C and anti-CTB IgYs can be used to prevent 
or treat cholera caused by either O1 or O139.  
Administration of anti-V.C IgY alone also showed 
some therapeutic eﬀect,  whereas anti-CTB IgY alone 
was not so eﬀective.  These results indicate that the 
elimination of the bacteria in the gut is more important 
than neutralization of the toxin.  This seems reason-
able.  In the case of oral vaccination that has been 
tried in humans,  the vaccine inducing antibodies 
against both bacteria and toxin is most eﬀective [16].
　 Anti-V.C IgY was very eﬀective for O139 infection 
but was not very eﬀective for O1 infection.  The rea-
son for this diﬀerence is not clear.  The behaviors of 
toxin production and ELISA reaction were not diﬀer-
ent between O1 and O139 cells.  Furthermore,  the 
mice challenged with O139 died earlier than those 
challenged with O1 (Fig.  2A and B),  indicating that 
the pathogenicity of O139 is stronger than that of O1 
in this mouse model.  On the banding proﬁle of 
Western blotting,  however,  some diﬀerences were 
observed (data not shown).  This time,  we immunized 
hens with mixed cells of O1 and O139.  In order 
clarify the above-mentioned phenomena,  we plan to 
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Table 1　 Reactivity of IgY to V. cholerae and cholera toxin
Antigen IgY
Source Concentration Concentration Control IgYOD
Anti VC-IgY
OD
Anti CTB-IgY
OD
Cholera Toxin 10µg/ml 100µg/ml 0.139±0.004 0.069±0.005 3.000±0.105
　1µg/ml 0.044±0.008 0.036±0.001 0.660±0.054
Cholera toxin B subunit 10µg/ml 100µg/ml 0.065±0.002 0.069±0.003 3.000±0.123
　1µg/ml 0.038±0.002 0.035±0.002 0.839±0.082
V. cholerae O1 E1 Tor (inaba) 7.5×106 CFU/ml
heat shock
100µg/ml 1.641±0.174 3.000±0.100 0.592±0.014
　1µg/ml 0.103±0.010 0.734±0.035 0.106±0.054
formalin
100µg/ml 1.702±0.071 3.000±0.125 0.812±0.027
　1µg/ml 0.220±0.018 0.944±0.020 0.167±0.017
V. cholerae O1 E1 Tor (ogawa) 7.5×106 CFU/ml
heat shock
100µg/ml 1.165±0.132 2.460±0.538 0.421±0.105
　1µg/ml 0.086±0.013 0.656±0.060 0.065±0.010
formalin
100µg/ml 1.438±0.088 3.000±0.040 0.709±0.186
　1µg/ml 0.128±0.087 0.874±0.259 0.108±0.049
V. cholerae O139　　　　　　7.5×106 CFU/ml
heat shock
100µg/ml 1.430±0.161 2.908±0.392 0.582±0.094
　1µg/ml 0.103±0.010 0.743±0.040 0.075±0.003
formalin
100µg/ml 1.588±0.100 3.000±0.183 0.884±0.032
　1µg/ml 0.220±0.007 1.229±0.040 0.173±0.004
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immunize the hens with each of these cells and charac-
terize the antibodies obtained.
　 The therapeutic eﬀects in the mice were similar 
across the range of administration intervals,  from 2h 
to 8h.  The mice were challenged with huge numbers 
of cells (3.75×1010 CFU); this amount is speculated 
to cause cholera more than 60ｵ of the time in humans 
[17,  18].  This indicated that administration of IgY 3 
or 4 times per day may be eﬀective in humans.
　 In prevention studies,  the occurrence of cholera 
was inhibited almost completely by mixing the anti-V.
C IgY with live O1 or O139 cells.  Also,  the IgY 
(mixture of anti-V.C and anti-CTB) demonstrated some 
good eﬀects even though it was administered 1h 
before the challenge with O1 Inaba cells.  It has been 
reported that oral administration of IgY in humans has 
good eﬀects on S. mutance and H. pylori infection with-
out severe side eﬀects including egg allergy [19,  20].  
Therefore,  we think the IgYs prepared this time can 
be used for cholera in humans,  too.  We plan to carry 
out these studies while carefully considering the dos-
age and dose interval of IgY administration,  as well as 
egg allergy.  We think the best administrative method 
is to mix them into dairy products,  powdered milk,  
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Fig. 1　 Eﬀect of anti-CTB IgY on elongation of CHO cells.  A,  Morphology of the CHO cells.  CHO cells were cultured in 24-well dishes 
(1).  CT treatment changed the cell morphology (2).  This morphological change was inhibited by preincubation of CT with 15µg/ml anti-
CTB IgY (3); B,  Eﬀect of diﬀerent amounts of IgY on elongation.  CT was treated with diﬀerent amounts of anti-CTB IgY and then reacted 
to the CHO cells.  The percentage of round cells to total cells was obtained by averaging the counts obtained by 10 microscope view 
ﬁleds.
5
Hirai et al.: Passive Oral Immunization by Egg Yolk Immunoglobulin (IgY) to Vib
Produced by The Berkeley Electronic Press, 2010
foods,  water,  or ORS to prevent or treat cholera in 
humans,  because they can supply water and nutrition 
in addition to antibody activity.  A large amount of IgY 
can be easily prepared in dry powder form and can be 
easily transferred,  without reducing its activity,  to a 
place where a big outbreak of cholera might occur.  
IgY is very simple to administer.  It can be easily 
given to people of all ages,  from babies to the elderly,  
even under serious or miserable conditions such as 
those occurring after a natural disaster.
Acknowledgments.　This work was supported by grants from the 
Ministry of Education,  Culture,  Sports,  Science,  and Technology of 
Japan.
168 Acta Med.  Okayama　Vol.  64,  No.  3Hirai et al.
0 10 20 30 40 50 60 70
0
20
40
60
80
100
Time (h)
Pe
rc
en
t s
ur
vi
va
l (
%
)
B
0 10 20 30 40 50 60 70
0
20
40
60
80
100
Time (h)
Pe
rc
en
t s
ur
vi
va
l (
%
)
C
A
0 10 20 30 40 50 60 70
0
20
40
60
80
100
Time (h)
Pe
rc
en
t s
ur
vi
va
l (
%
)
Fig. 2　 Therapeutic eﬀect of IgY on cholera in infant mice.  Four-day-old suckling mice were gastrointestinally inoculated with 50µl of O1 
or O139 cells (7.5×108 CFU/ml).  After 3hr,  the mice were then administered 50µl of anti-V.C IgY,  anti-CTB IgY,  or a mixture of 1mg/
ml of each at diﬀerent intervals.  A,  Inoculation of V. cholerae O1 El Tor (Inaba).  The mice were then administered the following at 2h 
intervals: PBS,  (●); control IgY,  (■) or anti-CTB IgY,  (△); anti-V.C IgY,  (◇); or both anti-CTB IgY and anti-V.C IgY,  (×); B,  
Inoculation with V. cholerae O139.  The mice were then administered the following at 2h intervals: PBS,  (●); anti-CTB IgY,  (■); and 
anti-V.C IgY,  (△); C,  Eﬀects of diﬀerent intervals.  After the challenge with V. cholerae O1 El Tor (Inaba),  the mice were administered 
with PBS,  (●); or a mixture of anti-V.C and -CTB IgYs at intervals of 2h,  (■); 4h,  (△); 6h,  (×); 8h,  (○); or 12h,  (□).
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Fig. 3　 Protective eﬀect of IgY.  A,  The simultaneous administration of cells and IgY.  O1 (Inaba) or O139 cells were mixed with anti-V.
C IgY and then injected into the stomach of the suckling mice.  (1) O1 cells alone,  (●); O1 cells with anti-V.C IgY [0.5mg/ml,  
(□); 1mg/ml,  (△); or 2mg/ml,  (×)].  (2) O139 cells alone,  (●); O139 cells with anti-V.C IgY 1mg/ml,  (■); B,  Eﬀect of pretreat-
ment with IgYs.  The suckling mice were ﬁrst administered PBS,  (●); or 1mg/ml of anti-V.C and -CTB mixed IgYs,  (■).  After 1h,  50µl 
(7.5×108 CFU/ml) of O1 organisms was challenged.  After 2h,  the mice were returned to their mothers and observed for up to 71h at 
30℃.
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